One Woman's Dramatic Insulin Reduction in Type 1 Diabetes Trial

A participant in the Eledon trial has reduced her daily insulin requirement to just a few units—a significant change that highlights ongoing research into slowing or halting Type 1 diabetes progression. We spoke with her about her experience.

cure researchbeta cellsadvancements

Key takeaways

Clinical trials are exploring new approaches that may substantially reduce insulin dependence in some people with Type 1 diabetes
Individual results in research studies can vary widely, and one person's outcome does not predict another's
Participants in trials gain access to experimental treatments and close medical monitoring
Advances in diabetes management tools, like long-wearing CGMs, continue to improve daily life alongside potential disease-modifying therapies

A Striking Change in Insulin Needs

Katie Bethand is a participant in the Eledon clinical trial who has experienced a remarkable reduction in her daily insulin requirement—down to just a few units per day. For someone who has managed Type 1 diabetes with standard insulin therapy, this represents a significant shift in what her body now needs to maintain blood sugar control.

While individual trial participants often see striking results, it's important to remember that clinical research measures effects across many people, and individual responses can differ considerably. Bethand's experience reflects the potential of the investigational approach being tested, but also underscores why rigorous trials are necessary to understand who may benefit and to what degree.

The Role of Clinical Trials in Type 1 Diabetes Research

Participants in clinical trials like Eledon's receive experimental treatments that are not yet available to the general public, along with intensive medical monitoring. This close oversight helps researchers understand both the benefits and any risks of new therapies.

Sharing patient stories from trials can inspire hope and raise awareness about ongoing research directions. At the same time, these individual accounts represent just one data point in the broader scientific picture needed to confirm whether a treatment is safe and effective for a wider population.

Living With Type 1 Diabetes Today

Beyond experimental therapies, people managing Type 1 diabetes also benefit from advances in everyday tools. Continuous glucose monitors (CGMs) that last longer and transmitters that can be removed and reapplied offer greater flexibility and convenience in daily diabetes management.

As research into disease-modifying treatments continues, these improvements in monitoring technology help people maintain better blood sugar control and quality of life in the present.

Evidence label

Origin: YouTube / Diabetes Nerd (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.